IDH2 and central nervous system cancer: Additional glioma subtypes may have recurrent point mutations in IDH1 and IDH2, platelet-derived growth factor receptor (PDGFR), cyclin-dependent kinase inhibitor 2A (CDKN2A) deletion, and tumor protein P53 (TP53) [13].